Director at Globus Medical (GMED) granted 15,000 stock options

Rhea-AI Filing Summary

Globus Medical Inc. director James R. Tobin received a grant of stock options on January 21, 2026. The award covers 15,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with no purchase price for receiving the options themselves.

According to the filing, these options will vest on January 1, 2027 and expire on January 21, 2036 if not exercised earlier. After this grant, Tobin holds 15,000 derivative securities directly, all from this option award. This represents routine equity-based compensation that aligns the director’s interests with the company’s long-term share performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TOBIN JAMES R

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$94.15	01/21/2026		A		15,000		(1)	01/21/2036	Class A Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. These options were granted on January 21, 2026, and will vest on January 1, 2027.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Globus Medical (GMED) disclose in this Form 4 for James R. Tobin?

The filing shows that director James R. Tobin received a grant of 15,000 stock options on January 21, 2026 to purchase Class A common stock of Globus Medical Inc.

What are the key terms of James R. Tobins stock options at Globus Medical (GMED)?

The stock options allow Tobin to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The options were granted on January 21, 2026 and carry an expiration date of January 21, 2036.

When do James R. Tobins Globus Medical (GMED) options vest?

The filing states that these options, granted on January 21, 2026, will vest on January 1, 2027, after which they become exercisable subject to their terms.

How many Globus Medical (GMED) derivative securities does James R. Tobin own after this transaction?

Following the reported transaction, Tobin beneficially owns 15,000 derivative securities, all from this stock option grant, held in direct ownership.

Is this Form 4 for Globus Medical (GMED) an insider buy or sell of common shares?

This Form 4 reports a stock option grant to a director, not a sale or purchase of existing common shares in the market. It reflects equity-based compensation rather than a trading transaction.